"SHPro" compound intake over 12 weeks significantly improves prostate-related symptoms and sexual function in patients suffering from benign prostatic hyperplasia, without causing severe side effects.
The study involved patients divided into treatment and control groups, undergoing four visits, and initiated medication intake from the second visit for a total duration of twelve weeks. The parameters evaluated included the International Prostate Symptom Score, International Index of Erectile Function, prostate-specific antigen level, testosterone, dihydrotestosterone, maximal urinary flow rate, residual urine volume, and a subjective improvement evaluation. In addition, safety tests consisted of clinical pathology tests and checking for adverse reactions.
A significant improvement was observed in the treatment group's total prostate symptom score, incomplete emptying score, erectile function score, sexual desire, intercourse satisfaction, and overall satisfaction. The subjective improvement evaluation also recognized significant enhancement. Although there were ten instances of mild adverse events such as gastrointestinal problems, skeletal pain, dermatitis, etc., no severe adverse reactions associated with the compound were observed.
